<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527367</url>
  </required_header>
  <id_info>
    <org_study_id>UMB-KKI-101</org_study_id>
    <nct_id>NCT04527367</nct_id>
  </id_info>
  <brief_title>Epidemiology and Long-term Outcome of Patients With VHD</brief_title>
  <acronym>BIA-WAD</acronym>
  <official_title>Epidemiology and Long-term Prognosis of Patients With Valvular Heart Diseases (BIA-WAD Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Valvular heart diseases are significant problem in Polish population. Coexistence of coronary&#xD;
      artery disease in patients with VHD increases the risk of death and affects further&#xD;
      therapeutic strategy. The aim of the study is analysis the epidemiology and the long-term&#xD;
      prognosis among patients with VHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Valvular heart diseases are significant problem in Polish population. Coexistence of coronary&#xD;
      artery disease in patients with VHD increases the risk of death and affects further&#xD;
      therapeutic strategy.&#xD;
&#xD;
      Patients with moderate and severe valvular heart diseases are included into the study. The&#xD;
      set of variables subject to interpretation consisted of demographic data, medical history,&#xD;
      result of coronary angiography, and type of applied percutaneous and surgical treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2006</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>3665 days</time_frame>
    <description>All-cause of mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>3665 days</time_frame>
    <description>Mocardial infarction, stent thrombosis, stroke or transient ischemic attack, urgent revascularization</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Valvular Disease</condition>
  <condition>Valvular Heart Disease</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Mitral Insufficiency and Aortic Stenosis</condition>
  <condition>Mitral Stenosis</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>VHD patients</arm_group_label>
    <description>Patients with moderate and severe valvular heart diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Innovative medical technologies in invasive cardiology and cardiac surgery</intervention_name>
    <description>A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.</description>
    <arm_group_label>VHD patients</arm_group_label>
    <other_name>Percutaneous coronary intervention</other_name>
    <other_name>Percutaneous aortic valve replacement</other_name>
    <other_name>Percutaneous interventional mitral regurgitation treatment</other_name>
    <other_name>Cardiosurgery</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients hospitalized in Medical University of Bialystok.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Valvular heart disease in moderate and severe stages&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Łukasz Kuźma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Bialystok</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Łukasz Kuźma, MD, PhD</last_name>
    <phone>48660720610</phone>
    <email>kuzma.lukasz@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paweł Kralisz, MD,Ph</last_name>
    <email>Paqral@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Invasive Cardiology, Medical University of Bialystok, The Medical University of Bialystok Clinical Hospital</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukasz Kuzma, MD, PhD</last_name>
      <phone>660720610</phone>
      <phone_ext>48</phone_ext>
      <email>kuzma.lukasz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pawel Kralisz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukasz Kuzma, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krzysztof Struniawski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slawomir Dobrzycki, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Kuźma Ł, Bachórzewska-Gajewska H, Kożuch M, Struniawski K, Pogorzelski S, Hirnle T, Dobrzycki S. Acute coronary syndromes and atherosclerotic plaque burden distribution in coronary arteries among patients with valvular heart disease (BIA-WAD registry). Postepy Kardiol Interwencyjnej. 2019;15(4):422-430. doi: 10.5114/aic.2019.90216. Epub 2019 Dec 8.</citation>
    <PMID>31933658</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuźma Ł, Małyszko J, Bachórzewska-Gajewska H, Niwińska MM, Kurasz A, Zalewska-Adamiec M, Kożuch M, Dobrzycki S. Impact of chronic kidney disease on long-term outcome of patients with valvular heart defects. Int Urol Nephrol. 2020 Nov;52(11):2161-2170. doi: 10.1007/s11255-020-02561-4. Epub 2020 Jul 14.</citation>
    <PMID>32661631</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Bialystok</investigator_affiliation>
    <investigator_full_name>Lukasz Kuzma</investigator_full_name>
    <investigator_title>Principal Investigator,</investigator_title>
  </responsible_party>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Mitral Insufficiency</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Chronic Kidney Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Mitral Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

